检索结果-南通市图书馆

Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma(2022 version)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2023年第7期11卷 1553-1564页

作者： Han Wang Jun Chen Xin Zhang Xia Sheng Xiao-Yan Chang Jie Chen Min-Shan Chen Hui Dong Guang-Jie Duan He-Ping Hu Zhi-Yong Huang Wei-Dong Jia Xiao-Qing Jiang Dong Kuang Shan-Shan Li Zeng-Shan Li Chang-Li Lu Shu-Kui Qin Xue-Shan Qiu Li-Juan Qu Chun-Kui Shao Feng Shen Guo-Ming Shi Su-Sheng Shi Yu-Jun Shi Hui-Chuan Sun Xiao-Dong Teng Bin Wang Zhan-Bo Wang Tian-Fu Wen Jia-Mei Yang Qiao-Qiao Yang Sheng-Long Ye Hong-Fang Yin Zhen-Gang Yuan Jing-Ping Yun Feng-Lin Zang Hong-Qi Zhang Li-Hong Zhang Jing-Min Zhao Jian Zhou Wei-Xun Zhou Jia Fan Xiao-Ping Chen Wan Yee Lau Yuan Ji Wen-Ming Cong chinese society of liver cancer of chinese anti-cancer association Digestive Disease Group of chinese society of Pathology,chinese Medical association chinese society of Pathology of chinese anti-cancer association Hepatic Surgery Group of chinese society of Surgery,chinese Medical association Biliary Tract Tumor Committee of China anti-cancer association chinese society of Clinical Oncology IDepartment of Pathology Eastern Hepatobilary Surgery HospitalNaval Medical UniversityShanghaiChina Department of Pathology the Affiliated Drum Tower HospitalNanjing University Medical SchoolNanjingJiangsuChina Department of Pathology Zhongshan HospitalFudan UniversityShanghaiChina Department of Pathology Minhang HospitalFudan Uni-versityShanghaiChina Department of Pathology Peking Union Medical College HospitalChinese Academy of Medical Sci-ences and Peking Union Medical CollegeBeijingChina Department of liver Surgery Sun Yat-Sen University Cancer CenterGuangzhouGuangdongChina Department of Pathology The First Affiliated HospitalArmy Medical UniversityChongqingChina Department of Hepatobiliary Medicine Eastern Hepatobiliary Surgery HospitalNaval Medical UniversityShanghaiChina Hepatic Surgery Center Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWu-hanHubeiChina Department of General Surgery The First Affliated Hospital of USTCDivision of Life Science and Medi-cineUniversity of Science and Technology of ChinaHefeiAnhuiChina Department of Biliary Surgery I Eastern Hepatobil-iary Surgery HospitalNaval Medical UniversityShanghaiChina Department of Pathology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiChina Department of Pathology The First Afiliated Hospital of Zhengzhou UniversityZhengzhou UniversityZhengzhouHenanChina Department of Pathology Xijing Hospi-talAir Force Medical UniversityXi'anShaanxiChina Department of Pathology West China HospitalSichuan UniversityChengduSichuanChina cancer Center of Jinling Hospital Nanjing University of Chinese MedicineNanjingJiangsuChina Department of Pathology The First Affiliated HospitalChina Medical UniversityShenyangLiaoningChina Department of Pathology The 900 Hospital of the Chinese People's Liberation Army Joint Logistics TeamFuzhouFujianChina Department of Pathology The Third Affiliated HospitalSun Yat-Sen UniversityGuangz

Intrahepatic cholangiocarcinoma(iCCA)can originate from the large bile duct group(segment bile ducts and area bile ducts),small bile duct group(septal bile ducts and interlobular bile ducts),and terminal bile duct group(bile ductules and canals of Hering)of the intrahepatic biliary tree,which can be histopathological corresponding to large duct type iCCA,small duct type iCCA and iCCA with ductal plate malformation pattern,and cholangiolocarcinoma,*** challenge in pathological diagnosis of above subtypes of iCCA falls in the distinction of cellular morphologies,tissue structures,growth patterns,invasive behaviors,immunophenotypes,molecular mutations,and surgical *** these reasons,this expert consensus provides nine recommendations as a reference for standardizing and refining the diagnosis of pathological subtypes of iCCA,mainly based on the 5th edition of the World Health Organization Classification of Tumours of the Digestive System.

关键词： Intrahepatic cholangiocarcinoma Pathology Histological type Immunohistochemistry Molecular variation

chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations(2023 edition)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese Medical Journal 2024年第9期137卷 1016-1018页

作者： The society of cancer Precision Medicine of chinese anti-cancer association The Lung cancer Expert Group of chinese Medical association Publishing House Baohui Han Hua Zhong 不详 Department of Respiratory Medicine Shanghai Chest HospitalSchool of MedicineShanghai JiaoTong UniversityShanghai 20030China Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine

Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed“forbidden territory”for immunotherapy.[1]With the continuous generation of evidence,immunotherapy is expected to bring hope for such NSCLC with oncogenic driver mutations after acquired tyrosine kinase inhibitor(TKI)***,given the intricate interplay between driven mutations,targeted therapy,and immune microenvironment,the efcacy of immunotherapy in advanced NSCLC patients with diverse oncogenic driver mutations remains a topic of ongoing *** this context,chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Oncogenic Driver Mutations(2022 edition)wasrst launched in 2022 by the society of cancer Precision Medicine of chinese anti-cancer association and the Lung cancer Expert Group of chinese Medical Journals,aiming to provide standardized treatment guidance for clinical practice.

关键词： immunotherapy cancer lung

在线全文

学校读者我要写书评

暂无评论

原发性肝癌规范化病理诊断方案专家共识

胃肠病学和肝病学杂志 2011年第5期20卷 393-395页

作者：无丛文铭中国抗癌协会肝癌专业委员会中国抗癌协会临床肿瘤学协作专业委员会中华医学会肝病学会肝癌学组全国肝胆肿瘤及移植病理协作组上海第二军医大学东方肝胆外科医院病理科

我国是肝癌高发国家之一。随着肝脏外科诊断、治疗技术的不断发展,我国肝癌临床病理诊断学也得到了快速发展,在肝癌病理标本的数量和类型上具有明显优势。为制订个体化治疗方案、提高肝癌远期疗效,临床上对肝癌病理报告的内容也提出了... 详细信息

我国是肝癌高发国家之一。随着肝脏外科诊断、治疗技术的不断发展,我国肝癌临床病理诊断学也得到了快速发展,在肝癌病理标本的数量和类型上具有明显优势。为制订个体化治疗方案、提高肝癌远期疗效,临床上对肝癌病理报告的内容也提出了新的要求。

关键词：肝癌病理学诊断

在线全文

学校读者我要写书评

暂无评论

肝癌局部消融治疗规范的专家共识

中华肝脏病杂志 2011年第4期19卷 257-259页

作者：中国抗癌协会肝癌专业委员会中国抗癌协会临床肿瘤学协作专业委员会中华医学会肝病学分会肝癌学组中国抗癌协会肝癌专业委员会中国抗癌协会临床肿瘤学协作专业委员会中华医学会肝病学分会肝癌学组

局部消融治疗是在影像技术的引导下对肿瘤靶向定位,用物理或化学的方法杀死肿瘤细胞;影像引导技术包括超声、CT和MRI;治疗途径有经皮、经腹腔镜手术和经开腹手术三种.局部消融治疗的特点：一是直接作用于肿瘤,具有高效快速的优势;二是... 详细信息

局部消融治疗是在影像技术的引导下对肿瘤靶向定位,用物理或化学的方法杀死肿瘤细胞;影像引导技术包括超声、CT和MRI;治疗途径有经皮、经腹腔镜手术和经开腹手术三种.局部消融治疗的特点：一是直接作用于肿瘤,具有高效快速的优势;二是治疗范围局限于肿瘤及其周围组织,对机体影响小,可以反复应用.局部消融治疗在过去20年左右发展迅速,已经成为继手术切除、介入治疗后的第三大肝癌治疗手段,而且由于其疗效确切,特别是在小肝癌的治疗方面,射频消融治疗的疗效与手术切除相近,因此,被认为是小肝癌的根治性治疗手段之一.

关键词：癌,肝细胞治疗学并发症局部消融

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

妊娠合并子宫颈癌诊治指南（2024年版）

中国实用妇科与产科杂志 2024年第10期 1003-1012页

作者： Cervical cancer Committee of China anti-cancer association Obstetrics and Gynecology society of chinese Medical Doctor association 中国抗癌协会宫颈癌专业委员会中国医师协会妇产科医师分会

1引言子宫颈癌是中国发病率最高的女性生殖道恶性肿瘤，同时也是妊娠期最常见的恶性肿瘤之一，发生率为（1.5～12）例/10万次妊娠，约占所有妊娠期恶性肿瘤的10%[1-3]，多数患者确诊时处于Ⅰ期[4-5]。在过去的10年中，我国妊娠合并子宫... 详细信息

1引言子宫颈癌是中国发病率最高的女性生殖道恶性肿瘤，同时也是妊娠期最常见的恶性肿瘤之一，发生率为（1.5～12）例/10万次妊娠，约占所有妊娠期恶性肿瘤的10%[1-3]，多数患者确诊时处于Ⅰ期[4-5]。在过去的10年中，我国妊娠合并子宫颈癌的发病率有所增高，主要与高龄妊娠的增加密切相关[6]。关于妊娠合并子宫颈癌的定义，广义是指妊娠期至分娩后6～12个月内新确诊的子宫颈癌，狭义是仅限定在妊娠期发现的子宫颈癌。

关键词：妊娠子宫颈癌指南

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

肝癌局部消融治疗规范的专家共识

胃肠病学和肝病学杂志 2011年第5期20卷 396-399页

作者：陈敏山陈敏华中国抗癌协会肝癌专业委员会中国抗癌协会临床肿瘤学协作专业委员会中华医学会肝病学分会肝癌学组

局部消融治疗是在影像技术的引导对肿瘤靶向定位,用物理或化学的方法杀死肿瘤组织;影像引导技术包括超声、CT和MRI;治疗途径有经皮、经腹腔镜手术和经开腹手术三种。局部消融治疗的特点：一是直接作用于肿瘤,具有高效快速的优势;二是治... 详细信息

局部消融治疗是在影像技术的引导对肿瘤靶向定位,用物理或化学的方法杀死肿瘤组织;影像引导技术包括超声、CT和MRI;治疗途径有经皮、经腹腔镜手术和经开腹手术三种。局部消融治疗的特点：一是直接作用于肿瘤,具有高效快速的优势;二是治疗范围局限于肿瘤及其周围组织,对机体影响小,可以反复应用。

关键词：肝癌治疗局部消融

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

在线全文

学校读者我要写书评

暂无评论

chinese Journal of cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Hospital Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Division of Therapeutic Drug Monitoring of chinese Pharmacological society(CPS) Expert Committee on Lymphoma of chinese society of Clinical Oncology(CSCO) Expert Committee on Leukemia of chinese society of Clinical Oncology(CSCO) society of Integrative Cardio-Oncology of China anti-cancer association(CACA) chinese society of Hematology of chinese Medical association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer(2024 edition)

在线全文

学校读者我要写书评

暂无评论

Radiation Medicine and Protection 2024年第2期5卷 59-67页

作者： Professional Committee of Radiation Oncology China anti-cancer association Branch of Radiation Oncology chinese Medical association Branch of Radiation Oncology TreatmentPhysician chinese Medical Doctor association Qingsong Pang Jun Wang Zhouguang Hui Wencheng Zhang 不详 Tianjin Medical University cancer Institute&Hospital Tianjin 300060China the Fourth Hospital of Hebei Medical University Shijiazhuang 050011China National cancer Center National Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Tianjin Medical University cancer Hospital China

Radiotherapy represents an essential treatment approach for esophageal *** recent years,immunotherapy combined with chemotherapy has become the first-line standard treatment for patients with advanced esophageal *** phase III studies on immunotherapy combined with radiotherapy for locally advanced esophageal cancer are currently *** evidence-based medical data are urgently needed to support the integration of immunotherapy and chemoradiotherapy as a new treatment strategy for patients with locally advanced esophageal *** consensus,formulated based on the latest study results,in-depth research,and thorough discussions,provides a comprehensive set of *** document extensively covers treatment strategies and evaluation methods for radiotherapy combined with immunotherapy across patients with operable esophageal cancer,inoperable locally advanced esophageal cancer,and advanced esophageal ***,common complications and radiation-related issues associated with radiotherapy combined with immunotherapy are discussed,serving as clinical *** expert group comprised members from the Professional Committee of Radiation Oncology,China anti-cancer association,the Branch of Radiation Oncology,chinese Medical association,and the Branch of Radiation Oncology Treatment Physician,chinese Medical Doctor association.

关键词： Esophageal squamous cell carcinoma Esophageal adenocarcinoma Immunotherapy Chemoradiotherapy Radiotherapy Expert consensus

Clinical significance of surgical resection for hepatocellular carcinoma with portal vein invasion:a nationwide cohort study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2024年第5期13卷 814-823,I0006-I0008页

作者： Hye-Sung Jo Pyoung-Jae Park Young-Dong Yu Yoo Jin Choi Se Hyeon Yu Dong-Sik Kim Korean liver cancer association Division of HBP Surgery and liver Transplantation Department of SurgeryKorea University College of MedicineSeoulRepublic of Korea Division of Transplantation and Vascular Surgery Department of SurgeryKorea University Guro HospitalKorea University College of MedicineSeoulRepublic of Korea

Background:Hepatocellular carcinoma(HCC)with portal vein invasion(PVI)is considered an advanced stage with a poor *** current guidelines recommend systemic treatment for HCC with PVI,surgical resection could produce acceptable outcomes in selected *** study aimed to identify the clinical significance of surgical resection for HCC with PVI patients using a large-scale nationwide ***:This retrospective,multicenter,observational cohort analyzed data from the Korean Primary liver cancer Registry.A total of 16,781 patients who were newly diagnosed with HCC between 2008 and 2018 were enrolled in this *** with worse Child-Turcotte-Pugh scores(≥7)or performance status(≥2)were *** them,998 patients who received treatment for HCC with PVI were included in the analysis and were divided into two groups:resection group of 151(15.1%)and palliative group of 847(84.9%)who received transarterial and systemic therapy according to the treatment *** matching the number and size of the tumors and model for end-stage liver disease(MELD)score between the groups,the final study cohort for analysis comprised 151(26.6%)patients in the resection group and 417(73.4%)in the palliative *** primary endpoints were overall survival(OS)and cancer-specific survival(CSS).Results:The number and maximum size of HCC did not differ between the resection and palliative groups after matching[1(range,1-5)vs.1(range,1-6),P=0.11 and 5.5(range,1.2-20.6)vs.6.0(range,1.0-20.5)cm,P=0.24,respectively].Tumor markers,including alpha-fetoprotein(AFP)and protein induced by vitamin K absence or antagonist-II(PIVKA-II),also did not differ between the groups(P=0.29 and P=0.36,respectively).The 5-year OS and CSS rates of the resection and palliative groups were 44.8%and 17.4%(P<0.001)and 47.7%and 18.6%(P<0.001),*** analysis showed that palliative treatment intent was the most significant risk factor for OS and CSS[odds ratio(OR

关键词： Hepatocellular carcinoma(HCC) portal vein invasion(PVI) overall survival(OS) cancer-specific survival(CSS) surgical resection